1131342-85-2

1131342-85-2 structure

Name: Finasteride-d9
Chemical Name: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-N-[2-(2H3)methyl(2H6)-2-propanyl]-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
CAS Number: 1131342-85-2
Molecular Formula: C₂₃H₂₇D₉N₂O₂
Molecular Weight: 381.60
Catalog: Signaling Pathways Metabolic Enzyme/Protease 5 alpha Reductase
Create Date: 2018-06-04 18:01:37
Modify Date: 2024-01-09 12:03:02
Finasteride-d9 is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].

Name	(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-N-[2-(2H3)methyl(2H6)-2-propanyl]-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Synonyms	(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-N-[2-(2H3)methyl(2H6)-2-propanyl]-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide MFCD07369399 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[1,1-di(methyl-d3)ethyl-2,2,2-d3]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-

Description	Finasteride-d9 is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> 5 alpha Reductase
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Flores E, et, al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003 May;3(3):225-37. [3]. Yun DK, et, al. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul). 2013 Jan;21(1):49-53. [4]. Sirinarumitr K, et, al. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218(8):1275-80.

Density	1.1±0.1 g/cm3
Boiling Point	576.6±50.0 °C at 760 mmHg
Molecular Formula	C₂₃H₂₇D₉N₂O₂
Molecular Weight	381.60
Flash Point	177.4±30.3 °C
Exact Mass	381.334167
LogP	3.24
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.524

1131342-85-2	98319-26-7
222989-99-3	1800205-94-0
154387-61-8	1338713-49-7
1325559-14-5	93449-32-2
61037-86-3	1346597-87-2